Zenas BioPharma, Inc.
ZBIO
$25.87
$1.204.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -141.23% | -357.08% | -33.39% | -37.51% | -20.77% |
| Total Depreciation and Amortization | -73.91% | -69.70% | -69.44% | -65.71% | -30.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 192.07% | 3,388.70% | 372.61% | 190.64% | 197.61% |
| Change in Net Operating Assets | -11.32% | -6.21% | -180.63% | 0.04% | -229.03% |
| Cash from Operations | -102.95% | -35.95% | -32.41% | -34.83% | -93.96% |
| Capital Expenditure | 88.89% | 100.00% | -- | 100.00% | 18.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 136.65% | -2,450.23% | 249.64% | -- | -- |
| Cash from Investing | 136.64% | -2,399.71% | 249.64% | -320,731.43% | -392,054.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 168,072.73% | 2,274.08% | -99.60% | 1,288.71% | 135.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -108.83% | 16,427.11% | -- | -- |
| Cash from Financing | 437,757.58% | 7,500.81% | -68.96% | -99.03% | 116.12% |
| Foreign Exchange rate Adjustments | -498.08% | -92.20% | 148.08% | -837.50% | -244.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 416.02% | 87.78% | -59.37% | -203.93% | -525.71% |